Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.

abstract：:Thirty-eight patients with small cell carcinoma of the bronchus resistant to initial chemotherapy with cyclophosphamide methotrexate and CCNU, were treated with VP16-213 alone in a dose of 120 mg/m2 i.v. on days 1, 3, and 5 every 3 weeks. Twelve patients died before three courses of treatment. In 26 patients who recei...

journal_title：Cancer chemotherapy and pharmacology

authors： Harper PG,Dally MB,Geddes DM,Spiro SG,Smyth JF,Souhami RL

更新日期：1982-01-01 00:00:00

abstract：:Cyclophosphamide pharmacokinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were greater than 20%, less than or equal to 30% over ideal body weight and 5 patients who were greater than 30% over ideal body weight. Cyclophosphamide plasma elimination half-live...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Reece P,Ahmann DL,Ingle JN

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

journal_title：Cancer chemotherapy and pharmacology

authors： Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

更新日期：2011-03-01 00:00:00

abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

journal_title：Cancer chemotherapy and pharmacology

authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

更新日期：2019-03-01 00:00:00

abstract：PURPOSE:Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine. METHODS:Combinational cytotoxic studies using viability tests and clonogen...

journal_title：Cancer chemotherapy and pharmacology

authors： Hernández P,Olivera P,Dueñas-Gonzalez A,Pérez-Pastenes MA,Zárate A,Maldonado V,Meléndez-Zajgla J

更新日期：2001-12-01 00:00:00

abstract：BACKGROUND/AIMS:Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited. We compared the efficacy and safety of sorafenib and hepatic arterial infusion chemotherapy (HAIC). METHODS:In this randomized, prospecti...

journal_title：Cancer chemotherapy and pharmacology

authors： Choi JH,Chung WJ,Bae SH,Song DS,Song MJ,Kim YS,Yim HJ,Jung YK,Suh SJ,Park JY,Kim DY,Kim SU,Cho SB

更新日期：2018-09-01 00:00:00

abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

journal_title：Cancer chemotherapy and pharmacology

authors： Daoud SS,Juliano RL

更新日期：1989-01-01 00:00:00

abstract：:P388 murine leukemic cells lines which were resistant (P388R) or sensitive (P388S) to adriamycin (adr) were used to evaluate the potential utility of in vitro clonogenic assays for detecting and quantitating the number of adr-resistant cells present in a cell mixture. The progeny of P388S cells that had been exposed f...

journal_title：Cancer chemotherapy and pharmacology

authors： Dong GW,Preisler HD,Priore R

更新日期：1984-01-01 00:00:00

abstract：BACKGROUND:The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical researc...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Yuan Z,Zhang Y,Cui Z,Li Y,Hou J,Liu X,Liu Z,Shi R,Tian Q,Wang J,Wang L

更新日期：2021-01-01 00:00:00

abstract：PURPOSE:Because of the recurrence of hepatocellular carcinoma (HCC) at the graft after liver transplantation, circulating HCC cells may be present during the anhepatic period. Intravenous doxorubicin (DOX) is used during the anhepatic period to combat these cells; however, pharmacokinetics data have been poorly analyze...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi S,Wada H,Hama N,Akita H,Kawamoto K,Eguchi H,Umeshita K,Doki Y,Mori M,Nagano H

更新日期：2013-12-01 00:00:00

abstract：:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplant...

journal_title：Cancer chemotherapy and pharmacology

authors： Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

更新日期：1996-01-01 00:00:00

abstract：:Plasma and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-OL) were measured fluorometrically after high-pressure liquid chromatography at 1, 3, and 24 h following one, nine, and 24 doses of 1.0 mg DXR/kg or one and eight doses of 4.0 mg DXR/kg, IP, to rats. Comparison of plasma levels of DXR found following...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters JH,Gordon GR,Kashiwase D,Acton EM

更新日期：1981-01-01 00:00:00

abstract：PURPOSE:Little information is available about changes in renal function after cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy for upper urinary tract-urothelial carcinoma (UUT-UC). METHODS:The data of patients ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cho KS,Joung JY,Seo HK,Cho IC,Chung HS,Chung J,Lee KH

更新日期：2011-04-01 00:00:00

abstract：:Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

journal_title：Cancer chemotherapy and pharmacology

authors： Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

更新日期：2016-02-01 00:00:00

abstract：:Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

journal_title：Cancer chemotherapy and pharmacology

authors： Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

更新日期：2005-05-01 00:00:00

abstract：PURPOSE:Amsalog, a derivative of 9-aminoacridine, is an inhibitor of topoisomerase II. Early studies of intravenous amsalog administered either once weekly, or daily for 3 days repeated every 3 weeks, showed that myelosuppression is the dose-limiting toxicity (DLT). Phase II studies showed only limited activity in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Fyfe D,Price C,Langley RE,Pagonis C,Houghton J,Osborne L,Woll PJ,Gardner C,Baguley BC,Carmichael J,Cancer Research Campaing Phase I\/II Trials Committee.

更新日期：2001-04-01 00:00:00

abstract：PURPOSE:2-Methoxyestradiol (2-ME) is a physiological metabolite of estrogen, which can inhibit growth of many types of tumor cells, including hepatocellular carcinoma, both in vitro and in vivo. The exact mechanisms of its action are still unclear. We have studied the mechanisms of growth inhibition of several of human...

journal_title：Cancer chemotherapy and pharmacology

authors： Kar S,Wang M,Carr BI

更新日期：2008-10-01 00:00:00

abstract：:Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; perip...

journal_title：Cancer chemotherapy and pharmacology

authors： Cassidy J,Paul J,Soukop M,Habeshaw T,Reed NS,Parkin D,Kaye SB

更新日期：1998-01-01 00:00:00

abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...

journal_title：Cancer chemotherapy and pharmacology

authors： Junor E,Davies J,Habeshaw T,Kaye S,Paul J,Rankin E,Reed N,Symonds RP

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

journal_title：Cancer chemotherapy and pharmacology

authors： Waud WR,Gilbert KS,Secrist JA 3rd

更新日期：2011-08-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

更新日期：2004-08-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

journal_title：Cancer chemotherapy and pharmacology

authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

更新日期：2016-07-01 00:00:00

abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

更新日期：1983-01-01 00:00:00

abstract：:Marimastat (BB-2516) is the first matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed phase I and II trials. Phase I studies involved healthy volunteers who received short courses of marimastat; these were well tolerated. Sympt...

journal_title：Cancer chemotherapy and pharmacology

authors： Steward WP

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND AND PURPOSE:Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Triclosan, a common antibiotic, functions by inhibiting the enoyl-reductase enzymes of type II fatty ...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu B,Wang Y,Fillgrove KL,Anderson VE

更新日期：2002-03-01 00:00:00

abstract：:A group of folate analogs of the 10-deaza-aminopterin series, which were designed on the basis of the results of an intensive biochemical and pharmacokinetic program, have been examined in therapy experiments utilizing a group of murine tumor models. These new analogs were found to be markedly superior to methotrexate...

journal_title：Cancer chemotherapy and pharmacology

authors： Sirotnak FM,DeGraw JI,Schmid FA,Goutas LJ,Moccio DM

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:An isolated pelvic perfusion technique using multiple agents was used both in patients with unresectable recurrent pelvic neoplasms and as a preoperative therapy for advanced pelvic malignancy. METHODS:The technique consisted of vascular occlusion via transfemoral balloon catheters, circulation and drug infusi...

journal_title：Cancer chemotherapy and pharmacology

authors： Wanebo HJ,Belliveau JF

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC). The aim of this phase-II study was to evaluate the efficacy and safety of this combination given weekly (3x) followed by a week off. The primary endpoint was: objective response ra...

journal_title：Cancer chemotherapy and pharmacology

authors： Ruiz M,Salvador J,Bayo J,Lomas M,Moreno A,Valero M,Bernabé R,Vicente D,Jiménez J,Lopez-Ladrón A

更新日期：2008-11-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Liu S,Tong X,Fan H

更新日期：2018-08-01 00:00:00

abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

更新日期：2015-03-01 00:00:00